NetScientific (GB:NSCI) has released an update.
NetScientific, a life sciences VC firm, reports that its portfolio company PDS Biotechnology has aligned with the FDA on a Phase 3 trial for an innovative HPV16-positive head and neck cancer treatment. The trial will assess the efficacy of their Versamune® platform in combination with pembrolizumab, and potentially, an additional drug, PDS01ADC. The trial aims to establish Versamune® HPV + pembrolizumab as the first targeted immunotherapy for this type of cancer, with strong support from key opinion leaders and numerous participating trial sites.
For further insights into GB:NSCI stock, check out TipRanks’ Stock Analysis page.
